These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1563386)

  • 1. Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid.
    Hjelm U; Kaustová J; Kubín M; Hoffner SE
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):51-4. PubMed ID: 1563386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined vs. single-drug studies of susceptibilities of Mycobacterium kansasii to isoniazid, streptomycin, and ethambutol.
    Tsang AY; Bentz RR; Schork MA; Sodeman TM
    Am J Clin Pathol; 1978 Nov; 70(5):816-20. PubMed ID: 717288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intra-macrophagic activity of antibiotics combinations against Mycobacterium marinum].
    Gevaudan MJ; Bollet C; Mallet MN; de Micco P
    Pathol Biol (Paris); 1991 May; 39(5):436-41. PubMed ID: 1652732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations.
    Hoffner SE; Hjelm U; Källenius G
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1285-8. PubMed ID: 8392308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of clinical efficacy of isoniazid and ethambutol in the treatment of nontuberculous mycobacteriosis based on in vitro susceptibility testing].
    Tsukamura M
    Kekkaku; 1989 Aug; 64(8):511-8. PubMed ID: 2811008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.
    Litvinov V; Makarova M; Galkina K; Khachaturiants E; Krasnova M; Guntupova L; Safonova S
    PLoS One; 2018; 13(9):e0203108. PubMed ID: 30222736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of opportunist mycobacteria to rifampicin and ethambutol.
    Yates MD; Collins CH
    Tubercle; 1981 Jun; 62(2):117-21. PubMed ID: 7303160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
    Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
    Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates.
    da Silva Telles MA; Chimara E; Ferrazoli L; Riley LW
    J Med Microbiol; 2005 Oct; 54(Pt 10):975-979. PubMed ID: 16157553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance.
    van Ingen J; Hoefsloot W; Mouton JW; Boeree MJ; van Soolingen D
    Int J Antimicrob Agents; 2013 Jul; 42(1):80-2. PubMed ID: 23664674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiometric susceptibility testing of Mycobacterium xenopi.
    Tortoli E; Simonetti MT
    J Chemother; 1995 Apr; 7(2):114-7. PubMed ID: 7666116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of ciprofloxacin against clinical isolates of mycobacteria resistant to antimycobacterial drugs.
    Marinis E; Legakis NJ
    J Antimicrob Chemother; 1985 Oct; 16(4):527-30. PubMed ID: 2933382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria.
    Banks J; Jenkins PA
    Thorax; 1987 Nov; 42(11):838-42. PubMed ID: 3424264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
    Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of ciprofloxacin in combination with standard antituberculous drugs against mycobacterium tuberculosis.
    Uttley AH; Collins CH
    Tubercle; 1988 Sep; 69(3):193-5. PubMed ID: 3151140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Distribution and drug resistance of nontuberculous
    Zhang J; Su JR; Ding BC; Liu JW; Yi JL; Yang XY; Wang NH; Wang SM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Mar; 40(3):210-214. PubMed ID: 28297817
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chemotherapeutic regimens for nontuberculous mycobacterial infection based on in-vitro susceptibility test results].
    Tsukamura M; Yamori S
    Kekkaku; 1990 May; 65(5):349-57. PubMed ID: 2168003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Portuguese in vitro antibiotic susceptibilities favor current nontuberculous mycobacteria treatment guidelines.
    Durão V; Silva A; Macedo R; Durão P; Santos-Silva A; Duarte R
    Pulmonology; 2019; 25(3):162-167. PubMed ID: 30309821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antimycobacterial activity between ethambutol and the beta-lactam drug cefepime.
    Abate G; Hoffner SE
    Diagn Microbiol Infect Dis; 1997 Jul; 28(3):119-22. PubMed ID: 9294701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the role of the mycobacterial cell envelope in the multiple drug resistance of atypical mycobacteria.
    Hoffner SE; Svenson SB
    Res Microbiol; 1991 May; 142(4):448-51. PubMed ID: 1871432
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.